Osimertinib Plus Chemo Prolongs PFS in EGFR/TP53-Mutated NSCLC

Originally published by our sister publication Clinical Oncology NewsBy Jennifer KulpaOsimertinib (Tagrisso, AstraZeneca) plus platinum–pemetrexed chemotherapy more than doubled progression-free survival (PFS) compared with osimertinib alone in patients with EGFR-mutated non–small cell lung cancer and concurrent TP53 mutations. This preliminary result, from the phase 3 TOP study, was presented at the 2026 European Lung Cancer Congress (presentation 2O).figure { display:inline-block;